AVAX Technologies Inc (AVXT)

[tencoin]

Jefferson Scientists' Results Raise Hopes for Ovarian Cancer Vaccine

Jefferson Medical College researchers have created what they believe may prove to be an effective ovarian cancer vaccine made from a patient's own cancer cells.
...

www.jefferson.edu/jeffnews/past/98/march/ovarian.html - 6k - 2014-02-24

------------------------------------------------------------------

Developing therapeutic cancer vaccines ...

Tumour-cell vaccines
Another treatment option is tumour-cell vaccines, which contain tumour cells obtained from the patient following surgery. These vaccines are intended to prevent disease recurrence in patients who have received prior treatment.

AVAX Technologies is developing a melanoma vaccine, which is marketed as MVax in Switzerland for the post-surgical treatment of stage III and IV malignant melanoma. The vaccine was developed using AC Vaccine technology licensed from the Thomas Jefferson University in the US, and consists of tumour cells conjugated to dinitrophenyl, a highly immunogenic hapten.

http://search.jefferson.edu/search?q=melanoma+vaccine&site=Jefferson&btnG=Search&entqr=0&entsp=a&sort=date%3AD%3AL%3Ad1&output=xml_no_dtd&client=jefferson&submit=GO&ud=1&oe=UTF-8&ie=UTF-8&proxystylesheet=jefferson

















.